HLA-B18 (B18) is an HLA-B serotype. The serotype identifies the more common HLA-B*18 gene products. [1] (For terminology help see: HLA-serotype tutorial) B*1801, the most common …

Immunogenetic association has been described for patients with d-penicillamine-induced myositis. In patients with d-penicillamine–induced myositis, the frequency of HLA-B18, -B35, and -DR4 …

2016年5月31日 · The survival analysis showed that the probability of F0–F2 patients progressing to advanced or severe fibrosis (F3–F4) was higher in HLA-B18 pos patients than in HLA-B18 …

HLA-B18 Is risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients; HLA-A*31:01 and HLA-B*15:02 alleles confer susceptibility to carbamazepine-induced severe …

HLA-B18/NY-ESO-1 88–96 and HLA-A2/NY-ESO-1 157–165 tetramers were used in combination with ICS for IFN-γ to positively identify the antigen-specific T CD8+. As expected, peptide …

We report a new HLA-B18 subtype (B*1806) which was serologically detected in a Spanish Caucasian individual as a B18 Bw4-associated antigen. Complete coding region sequencing …

HLA-B*18:01 and HLA-DRB1*01, being unassociated with HLA-B*35, are genetic risk factors which seem to be population-independent SAT markers.

In the present study we have taken advantage of the conservation and diabetogenicity of the B18-DR3 CEH, to identify disease-associated variability while controlling for LD with classical HLA …

2016年10月25日 · We identified HLA-B18 as a factor associated with the progression of liver fibrosis (by at least one stage: HLA-B18 pos 81.1% vs HLA-B18 neg 38.9%; P =0.017). The …

HLA-B18 pos patients more frequently had a higher and faster fibrosis progression rate (73.3%; 24 (IQR: 8-29) months) than HLA-B18 neg patients (38.2%; 34.5 (IQR: 14.7-51.2) months). …